zurück

Pembrolizumab (new indication: cervical cancer with PD-L1 expression with a CPS ≥ 1, in combination with or without bevacizumab)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Cervical cancer
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  1. Adults for whom pembrolizumab is the first-line therapy: Therapy at the physician's discretion, appropriate therapies include:
    - cisplatin in combination with paclitaxel ± bevacizumab OR
    - carboplatin in combination with paclitaxel ± bevacizumab (only for cisplatin-pretreated patients or patients unsuitable for cisplatin) OR
    - cisplatin in combination with topotecan OR'carboplatin in combination with topotecan (only for cisplatin-pretreated patients unsuitable for cisplatin) OR
    - paclitaxel in combination with topotecan ± bevacizumab (only for patients unsuitable for platinum-containing chemotherapy)
     
  2. Adults with first-line chemotherapy and for whom further antineoplastic therapy is being considered: Therapy at the physician's discretion, appropriate therapies include:
    - nab-paclitaxel OR
    - vinorelbine OR
    - liosfamide OR
    - topotecan OR
    - pemetrexed OR
    - irinotecan OR
    ​​​​​​​- pembrolizumab (for patients wiht PD-L1 positive metastatic cervical cancer)